AVEO: Data Provides Rationale For Investigation Of AV-203 As Anticancer Therapy

By RTT News, 
A A A


(RTTNews.com) - AVEO Oncology ( AVEO ) announced the presentation of results from a first-in-human Phase 1 study of AV-203, AVEO's ErbB3 (HER3) inhibitory antibody candidate. The company said the study established a recommended Phase 2 dose of AV-203, demonstrated good tolerability and promising early signs of activity, and reached the maximum planned dose of AV-203 monotherapy.

The recommended Phase 2 dose was established at 20mg/kg intravenously every 2 weeks. No anti-drug antibodies were detected, and pharmacokinetic results indicated a dose-proportional increase in levels of AV-203.

For comments and feedback: contact editorial@rttnews.com

http://www.rttnews.com



This article appears in: Technology

Referenced Stocks: AVEO

RTT News


More from RTT News:

Related Videos

Your Car Is Spying on You
Your Car Is Spying on You           

Stocks

Referenced

Most Active by Volume

73,078,214
  • $30.33 ▼ 3.90%
57,046,796
  • $15.52 ▲ 0.45%
51,290,831
  • $100.57 ▲ 0.04%
39,855,468
  • $8.13 ▲ 1.37%
31,693,544
  • $5.50 ▲ 20.35%
31,532,510
  • $10.33 ▲ 0.78%
31,526,753
  • $39.10 ▲ 47.21%
28,366,542
  • $26.36 ▲ 1.19%
As of 8/20/2014, 04:04 PM